32 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 26 Phase 3, 10 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Completed 24, Recruiting 1, Terminated 1 |
| Phase 2 | 10 | Completed 6, Terminated 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 7 | Completed 6, Active not recruiting 1 |
Follow Nobelpharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MSA-01 in Multiple System Atrophy MSA-01, Placebo - Multiple System Atrophy (MSA) | Phase 3 | Recruiting | Tokyo University | 140 | 2026-02-09 | 2026-03-04 |
| Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans Sirolimus 0.2% - Acanthosis Nigricans | Phase 2 | Completed | Narrows Institute for Biomedical Research | 5 | 2025-03-01 | 2025-11-28 |
| In-office Repair of Chronic Tympanic Membrane Perforations Fibroblast Growth Factor 2, Saline control - Chronic Tympanic Membrane Perforation | Phase 1 / Phase 2 | Active not recruiting | D. Bradley Welling, MD, PhD | 20 | 2024-06-15 | 2026-06-24 |
| NPC-06 to Pain Associated With Acute Herpes Zoster NPC-06, Placebo - Acute Pain in Herpes Zoster | Phase 3 | Completed | Nobelpharma | 51 | 2022-08-05 | 2023-09-28 |
| Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC NPC-12Y gel, NPC-12Y placebo gel - Tuberous Sclerosis Complex | Phase 3 | Completed | Nobelpharma | 43 | 2022-06-01 | 2024-11-22 |
| Efficacy Confirmation Study of NPC-09 NPC-09, NPC-09 placebo - GNE Myopathy, Distal Myopathy With Rimmed Vacuoles (DMRV) | Phase 3 | Completed | Nobelpharma | 14 | 2021-02-08 | 2022-05-16 |
| A Phase II/III Study of Sargramostim Sargramostim, Placebo - COVID-19 | Phase 2 / Phase 3 | Completed | Nobelpharma | 70 | 2020-12-17 | 2024-07-19 |
| An Additional Study of NPC-22 in Healthy Adult Males NPC-22, NPC-22 Placebo - Safety and Pharmacokinetics | Phase 1 | Completed | Nobelpharma | 32 | 2020-07-20 | 2022-02-07 |
| A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I NPC-12G gel - Neurofibromatosis | Phase 3 | Terminated | Nobelpharma | 100 | 2020-07-08 | 2022-05-24 |
| A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection NPC-21 Low dose, NPC-21 High dose, NPC-21 Placebo - Cytomegalovirus Disease | Phase 2 | Completed | Nobelpharma | 87 | 2020-06-01 | 2025-06-17 |
| NPC-06 to Acute Pain in Herpes Zoster NPC-06 - Acute Pain in Herpes Zoster | Phase 2 | Terminated | Nobelpharma | 16 | 2019-11-21 | 2021-07-01 |
| A Study of NPC-22 in Healthy Adult Males NPC-22, NPC-22 Placebo - Healthy Adult Subjects | Phase 1 | Completed | Nobelpharma | 40 | 2019-11-19 | 2020-08-06 |
| NPC-12G Gel 0.2% Sirolimus PK Bridging Study NPC-12G Gel 0.2%, Rapamune® 2 mg tablet - Bioavailability Study | Phase 1 | Completed | Nobelpharma | 12 | 2019-05-31 | 2020-03-06 |
| Phase II Clinical Trial of NPC-06 in Patients With Neuropathic Pain in Cancer NPC-06 - Neuropathic Pain in Cancer | Phase 2 | Terminated | Nobelpharma | 7 | 2019-04-03 | 2020-11-16 |
| Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets sirolimus - Bioequivalence Study | Phase 1 | Completed | Nobelpharma | 10 | 2018-12-05 | 2019-02-25 |
| Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7) NPC-15 and/or Placebo - Qt Interval, Variation in | Phase 1 | Completed | Nobelpharma | 12 | 2018-04-03 | 2018-06-28 |
| Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders NPC-15 - Sleep Disorders, Neurodevelopmental Disorder | Phase 3 | Completed | Nobelpharma | 99 | 2016-06-21 | 2019-04-16 |
| Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders NPC-15 Granules Lower Dose, NPC-15 Granules Higher Dose, NPC-15 Placebo Granule - Sleep Disorders, Autism Spectrum Disorder | Phase 2 / Phase 3 | Completed | Nobelpharma | 196 | 2016-06-16 | 2019-04-16 |
| Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) NPC-12G gel, Placebo gel - Tuberous Sclerosis, Angiofibroma | Phase 3 | Completed | Nobelpharma | 62 | 2015-12-01 | 2017-02-02 |
| Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex NPC-12G gel - Tuberous Sclerosis, Angiofibroma | Phase 3 | Completed | Nobelpharma | 94 | 2015-12-01 | 2019-02-20 |
Showing 20 of 38. Sign in to see all of them.
Dysmenorrhea (6) · Tuberous Sclerosis (3) · Angiofibroma (2) · Glioma (2) · Plaque, Amyloid (2) · Sleep Wake Disorders (2) · Acanthosis Nigricans (1) · Acute Pain (1) · Apnea (1) · Autism Spectrum Disorder (1) · COVID-19 (1) · Cytomegalovirus Infections (1) · Distal myopathy, Nonaka type (1) · Epilepsy (1) · Hepatolenticular Degeneration (1)
Ethinyl Estradiol (4) · Norethindrone (3) · Administration, Oral (2) · Melatonin (2) · Sirolimus (2) · Fibroblast Growth Factor 2 (1) · Gels (1) · Levonorgestrel (1) · NPC 16 (1) · Oxcarbazepine (1) · Sugars (1) · Tablets (1) · Zinc Acetate (1) · arbekacin (1) · caffeine citrate (1)
Japan (23) · United States (4)
Naoki Terakawa, M.D.,Ph.D. (5) · Koudou Ishii, M.D. (2) · Takefumi Matuo, MD (2) · Yushiro Yamashita, MD, PhD (2) · D Bradley Welling, MD, PhD (1) · Eiji Nakagawa, M.D. (1) · Hirofumi Komaki, MD, PhD (1) · Jared Jagdeo, MD MS (1) · Mari Wataya-Kaneda, MD, PhD (1) · Mari Wataya-Kaneda,, MD, PhD (1) · Masaharu Hayashi, MD, PhD (1) · Masao Mastutani, M.D., D.M.Sci. (1) · Mikio Momoeda, MD, PhD (1) · Soichiro Shibui, MD, PhD (1) · Susumu Itoh, MD, PhD (1)
PMID 31392541, PMID 21078496, PMID 21420678, PMID 27717552, PMID 29800026, PMID 32385845, PMID 32912180, PMID 37523477, PMID 37568154, PMID 37729076, PMID 38149403, PMID 38700045, PMID 40072882